CLINICAL_TRIALS
trial_result
· 2022-02-14
Clinical Trial Update: A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes [Phase 3]
Summary
Phase 3 long-term safety study of tirzepatide (LY3298176) in participants with type 2 diabetes has completed with results posted in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2022-02-14